G6PD Test (Qualitative) Analysis at Lahore PCR Lab

G6PD Test (Qualitative) at Lahore PCR Lab

The Glucose-6-Phosphate Dehydrogenase (G6PD) qualitative test is a specialized laboratory investigation designed to screen for G6PD enzyme deficiency, a hereditary genetic disorder that affects red blood cells. G6PD is a vital cytosolic enzyme present in all human cells, but it plays an exceptionally critical role in mature erythrocytes (red blood cells). It catalyzes the first step in the pentose phosphate pathway, converting glucose-6-phosphate into 6-phosphoglucono-D-lactone, a reaction that reduces nicotinamide adenine dinucleotide phosphate (NADP) to NADPH. This generated NADPH is the primary source of reducing equivalents in red blood cells, which is essential for maintaining glutathione in its reduced state. Reduced glutathione acts as a cellular antioxidant, neutralizing reactive oxygen species (ROS) and protecting the erythrocyte membrane and hemoglobin from oxidative damage. Because mature red blood cells lack mitochondria and nuclei, they cannot synthesize new proteins and are entirely dependent on G6PD for defense against oxidative stress.

When an individual with G6PD deficiency is exposed to oxidative stressors—such as certain medications, infections, or specific foods like fava beans—the lack of sufficient NADPH leads to the accumulation of free radicals. This causes the oxidation of hemoglobin, which precipitates as Heinz bodies within the red blood cells. As these damaged erythrocytes pass through the spleen, splenic macrophages bite out these precipitated inclusions, forming characteristic “bite cells” and leading to intravascular or extravascular hemolysis. The G6PD Test (Qualitative) at Lahore PCR Lab serves as an essential screening tool to identify individuals with this deficiency, allowing for proactive clinical management and the avoidance of life-threatening hemolytic crises.

The qualitative analysis of G6PD typically utilizes screening methods such as the fluorescent spot test or the methemoglobin reduction test. The fluorescent spot test, recognized as a highly reliable qualitative screening assay, detects the generation of NADPH under ultraviolet light. When blood is incubated with glucose-6-phosphate and NADP, normal samples will produce NADPH, which fluoresces brightly under UV light. Deficient samples, lacking adequate enzyme activity, will fail to produce fluorescence or show significantly diminished intensity. This qualitative assessment provides a rapid, binary (normal versus deficient) or semi-quantitative determination of enzyme activity, making it an invaluable diagnostic tool in clinical pathology, hematology, and pediatrics.

This test is of paramount clinical importance in Lahore, Pakistan, where genetic variations and consanguineous marriages contribute to a notable prevalence of inherited hematological disorders. By screening patients, particularly newborns and individuals scheduled to start oxidative drug therapies, healthcare providers can prevent acute hemolytic anemia, severe neonatal hyperbilirubinemia, and potential neurological complications such as kernicterus. The diagnostic value of this test lies in its ability to deliver rapid, accurate, and cost-effective screening, enabling clinicians to make informed therapeutic decisions and safeguard patient health.

Clinical Procedure: What to Expect

Patient Preparation

Appropriate patient preparation is critical to ensure the clinical accuracy of the qualitative G6PD test and to prevent false or misleading results. Patients and healthcare providers must adhere to the following guidelines prior to sample collection:

• No Fasting Required: There is generally no requirement for dietary fasting before the test. The patient may eat and drink normally unless instructed otherwise for concurrent laboratory investigations.
• Timing Relative to Hemolytic Episodes: The test should ideally not be performed during or immediately after an acute hemolytic crisis. During a hemolytic episode, older, G6PD-deficient red blood cells are preferentially destroyed, leaving behind a younger population of red blood cells (reticulocytes). Reticulocytes possess significantly higher levels of G6PD enzyme activity than mature erythrocytes, which can lead to a false-normal qualitative result despite the patient being genetically deficient. It is recommended to wait several weeks after the resolution of an acute episode before testing.
• Blood Transfusion History: Patients must not have received a blood transfusion within the preceding 3 months. Transfused donor red blood cells contain normal levels of G6PD, which will temporarily mask the patient’s native enzyme deficiency, yielding a false-negative (normal) result.
• Medication Review: Inform the ordering physician and the laboratory staff at Lahore PCR Lab of all current medications, over-the-counter drugs, and herbal supplements. Certain medications should be documented, especially if they are known oxidative agents.
• Dietary Disclosure: Document any recent consumption of fava beans or exposure to chemical agents like naphthalene (mothballs), as these can trigger active hemolysis and alter the clinical interpretation of the test.

During the Procedure

The G6PD qualitative test is performed on a peripheral blood sample collected via standard venipuncture. The procedure is conducted by a trained phlebotomist at Lahore PCR Lab and involves the following steps:

• Patient Identification and Verification: The phlebotomist verifies the patient’s identity using at least two unique identifiers and confirms that prep guidelines (such as transfusion history) have been met.
• Site Selection and Cleansing: The phlebotomist identifies a suitable vein, typically the median cubital vein in the antecubital fossa of the arm. The skin over the selected site is thoroughly cleansed with an antiseptic solution (usually 70% isopropyl alcohol) and allowed to air dry to prevent specimen contamination or hemolysis.
• Venipuncture: A tourniquet is applied briefly above the selected site to increase venous pressure. A sterile, single-use needle is inserted into the vein, and blood is drawn into a vacuum collection tube containing an anticoagulant, typically ethylenediaminetetraacetic acid (EDTA, purple top) or heparin (green top).
• Post-Collection Care: Once the specimen is collected, the needle is withdrawn, and immediate, gentle pressure is applied to the puncture site with a sterile gauze pad to promote hemostasis and prevent hematoma formation. A small adhesive bandage is applied.
• Sample Inversion: The collection tube is gently inverted several times immediately after collection to ensure thorough mixing of the blood with the anticoagulant, preventing micro-clot formation which could interfere with the analysis.
• Newborn Collection (Heel Prick): For neonates, the sample may be collected via a heel prick. The infant’s heel is warmed, cleansed, and punctured with a sterile lancet. The blood is collected directly into micro-collection tubes or onto specialized filter paper cards (Guthrie cards) for screening.
• Duration and Safety: The entire venipuncture procedure takes approximately 3 to 5 minutes. It is highly safe, with minimal risks limited to transient localized discomfort, minor bruising, or rare localized infection at the puncture site.

When is a G6PD Test (Qualitative) Performed?

Neonatal Jaundice Evaluation

Neonatal hyperbilirubinemia is a common clinical presentation in newborns, but when jaundice appears within the first 24 hours of life, is unusually severe, or is prolonged, G6PD deficiency must be suspected. In Lahore, Pakistan, screening newborns with unexplained or exaggerated jaundice is a critical clinical practice. G6PD deficiency impairs the liver’s ability to conjugate and excrete bilirubin due to the rapid breakdown of red blood cells. If left undiagnosed and untreated, extreme hyperbilirubinemia can lead to bilirubin encephalopathy (kernicterus), causing permanent neurological damage, cerebral palsy, and sensorineural hearing loss. Performing the qualitative test early allows for prompt phototherapy or exchange transfusion interventions.

Pre-Medication Screening for Oxidant Drugs

Physicians routinely request a qualitative G6PD test before prescribing medications known to induce oxidative stress in red blood cells. Key pharmacological agents include antimalarials (such as primaquine and pamaquine), sulfonamides (like sulfamethoxazole used in co-trimoxazole), dapsone, nitrofurantoin, and rasburicase. Administering these drugs to a G6PD-deficient individual can precipitate sudden, severe intravascular hemolysis, leading to acute renal failure and profound anemia. Screening patients at Lahore PCR Lab prior to initiating these therapies is a vital safety measure that guides clinicians toward alternative, safer pharmacological options.

Investigation of Acute Hemolytic Episodes

When a patient presents with sudden-onset clinical symptoms of hemolysis—such as acute fatigue, pallor, unexplained back or abdominal pain, dark tea-colored urine, and scleral icterus (yellowing of the eyes)—a G6PD test is indicated. These episodes are often triggered by an underlying viral or bacterial infection, which generates inflammatory cytokines and reactive oxygen species that overwhelm the deficient erythrocyte’s antioxidant capacity. Identifying G6PD deficiency as the root cause of the acute hemolytic event helps clinicians manage the patient’s hydration, monitor renal function, and avoid further exposure to potential triggers.

Investigation of Favism Symptoms

Favism is a classic clinical manifestation of G6PD deficiency, characterized by an acute, severe hemolytic reaction occurring within hours to days after the ingestion of fava beans (Vicia faba) or inhalation of pollen from the fava plant. Fava beans contain vicine and convicine, glucosides that are metabolized into divicine and isouramil, highly active oxidant compounds. This condition is particularly common in pediatric populations. When a child presents with sudden anemia and hemoglobinuria after consuming fava beans, a qualitative G6PD test is performed to confirm the diagnosis and educate the family on strict dietary avoidance.

Unexplained Chronic Nonspherocytic Hemolytic Anemia

While most G6PD-deficient individuals are asymptomatic under normal physiological conditions, some carry rare, severe genetic variants (classified as WHO Class I) that cause chronic, ongoing hemolysis even in the absence of external oxidative triggers. These patients present with persistent mild-to-moderate anemia, reticulocytosis, and splenomegaly. A qualitative G6PD test, followed by quantitative enzyme assays if necessary, is performed to differentiate this condition from other hereditary hemolytic anemias, such as hereditary spherocytosis or pyruvate kinase deficiency, ensuring appropriate long-term hematological management.

What Does a G6PD Test (Qualitative) Detect?

The qualitative G6PD test is designed to detect the presence or absence of adequate glucose-6-phosphate dehydrogenase enzyme activity within the patient’s red blood cells. Specifically, the test evaluates and detects several clinical and physiological states, including:

• Adequate G6PD Enzyme Activity: Confirms that the red blood cells possess sufficient enzyme levels to withstand standard physiological and environmental oxidative stress.
• Severe G6PD Deficiency: Detects a critical lack of enzyme activity, typically seen in hemizygous males who carry the mutated gene on their single X chromosome.
• Moderate G6PD Deficiency: Identifies partial enzyme deficiency, which may be associated with specific genetic variants common in Asian populations.
• Intermediate or Borderline Enzyme Activity: Often detected in heterozygous female carriers who, due to random X-chromosome inactivation (lyonization), possess a mosaic population of both normal and deficient red blood cells.
• Susceptibility to Drug-Induced Hemolysis: Identifies individuals at high risk of developing acute hemolytic anemia if exposed to oxidant drugs like primaquine or dapsone.
• Susceptibility to Favism: Detects the underlying biochemical vulnerability to severe hemolytic reactions from fava bean consumption.
• Infection-Induced Hemolytic Risk: Identifies patients whose red blood cells are vulnerable to lysis during acute bacterial or viral infections.
• Risk of Neonatal Hyperbilirubinemia: Detects newborns who are genetically predisposed to developing severe, rapid-onset jaundice.
• Presence of WHO Class I Variants: Assists in identifying rare mutations causing chronic nonspherocytic hemolytic anemia.
• Presence of WHO Class II Variants: Detects severe deficiency (<10% normal activity) associated with acute hemolytic episodes from various stressors.
• Presence of WHO Class III Variants: Detects moderate deficiency (10-60% normal activity) where hemolysis occurs only with significant oxidative stress.
• False-Negative (Normal) Results Due to Reticulocytosis: Detects the confounding effect of a high reticulocyte count during an active hemolytic crisis, which can temporarily mask a true deficiency.
• False-Negative Results Due to Recent Transfusion: Identifies the presence of normal donor red blood cells that interfere with the detection of the patient’s native deficiency.
• In vitro Hemolysis: Detects pre-analytical sample degradation or mechanical lysis during collection, which may necessitate a repeat sample.
• Inadequate Sample Volume: Identifies insufficient blood collection that prevents the accurate execution of the qualitative assay.
• Anticoagulant Interference: Evaluates whether the correct tube (EDTA or heparin) was used, as incorrect anticoagulants can affect enzyme stability.
• Sample Degradation due to Temperature: Detects loss of enzyme activity resulting from improper storage or delayed transport of the specimen to the laboratory.
• Extreme Leukocytosis Interference: Identifies potential analytical interference in patients with extremely high white blood cell counts, which contain their own G6PD enzyme.
• Profound Thrombocytosis Interference: Detects potential false-normal results caused by high platelet counts, as platelets also contain active G6PD.
• Hemoglobinuria Correlation: Helps correlate clinical findings of dark urine with intravascular hemolysis secondary to enzyme deficiency.
• Heinz Body Formation Correlation: Correlates qualitative deficiency with the presence of oxidized, precipitated hemoglobin inclusions in red blood cells.
• Bite Cell and Blister Cell Correlation: Links qualitative enzyme deficiency with characteristic morphological abnormalities observed on a peripheral blood smear.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that timely diagnostic results are crucial for effective clinical decision-making, particularly when screening newborns or preparing patients for urgent medical treatments. Utilizing advanced automated diagnostic systems and strict quality control protocols, the laboratory ensures high precision and rapid processing for the G6PD qualitative test.

The standard turnaround time for the G6PD Test (Qualitative) at Lahore PCR Lab is typically within 24 to 48 hours from the time of sample collection. Once the analysis is completed and verified by a consultant pathologist, patients and referring physicians are immediately notified via an automated SMS alert. Reports can be securely accessed, viewed, and downloaded in PDF format through the official Lahore PCR Lab online patient portal. Physical copies of the reports are also available for collection at the main laboratory facility and designated collection centers across Lahore, Pakistan, ensuring maximum convenience and seamless integration into the patient’s healthcare journey.

G6PD Test (Qualitative) Findings Overview

The following table outlines the key parameters evaluated during a qualitative G6PD assessment, along with their corresponding normal and possible abnormal findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
G6PD Enzyme Activity (Qualitative)	Normal / Adequate enzyme activity detected (bright fluorescence or normal reduction)	Deficient / Decreased enzyme activity (no fluorescence or delayed reduction)
Red Blood Cell (RBC) Count	Normal range (typically 4.5 – 5.9 x 10^12/L for males, 4.1 – 5.1 x 10^12/L for females)	Decreased RBC count (anemia) during acute hemolytic episodes
Hemoglobin (Hb) Levels	Normal range (typically 13.5 – 17.5 g/dL for males, 12.0 – 15.5 g/dL for females)	Sudden drop in hemoglobin levels during oxidative stress or hemolytic crisis
Reticulocyte Count	Normal range (0.5% – 1.5% of total RBCs)	Significantly elevated (reticulocytosis) post-hemolysis, indicating bone marrow compensatory response
Serum Bilirubin (Total & Indirect)	Normal levels (Total: 0.2 – 1.2 mg/dL; Indirect: <0.8 mg/dL)	Elevated indirect (unconjugated) bilirubin, reflecting rapid erythrocyte destruction
Serum Haptoglobin	Normal range (30 – 200 mg/dL)	Markedly decreased or undetectable haptoglobin, indicating significant intravascular hemolysis
Heinz Bodies (Peripheral Smear)	Absent	Present during acute oxidative stress before splenic clearance
Urinalysis (Hemoglobin)	Negative for free hemoglobin	Positive (hemoglobinuria), resulting in dark, tea-colored or cola-colored urine

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for G6PD Test (Qualitative)?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified pathologists, hematologists, and clinical laboratory technologists dedicated to diagnostic excellence.
• Patient-Focused Care: We prioritize patient comfort and safety, ensuring a compassionate and professional environment during sample collection.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict internal and external quality control standards to deliver highly accurate and reproducible results.
• Professional Reporting: All qualitative G6PD reports are thoroughly reviewed and signed off by consultant pathologists before release.
• Modern Diagnostic Approach: We utilize advanced screening methodologies and automated systems to minimize human error and enhance diagnostic precision.
• Comfortable Environment: Our state-of-the-art collection centers in Lahore are designed to provide a clean, hygienic, and stress-free experience for patients of all ages, including infants.
• Convenient Location: Located centrally in Lahore, Pakistan, our main facility and collection points offer easy access for patients across the city.
• Commitment to Accurate Diagnosis: We are dedicated to providing reliable diagnostic insights that empower clinicians to make timely, life-saving medical decisions.